ReviewDrugs & aging2022
Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.
Review in Drugs & aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 5 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Effects of dance movement therapy and other dance-related interventions on depressive symptoms: a meta-analysis of evidence in the past decade.European archives of psychiatry and clinical neuroscience · 2026Pooled it
- The effect of physical exercise on apathy in older adults: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Cognitive behavioral therapy for anxiety and depression symptoms in people of Parkinson's disease: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2025Pooled it
- Non-pharmacological therapies for treating non-motor symptoms in patients with Parkinson's disease: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2024Pooled it
- Neuroinflammation in Parkinson's Disease: From Gene to Clinic: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson's disease in China: a randomized clinical trial.BMC complementary medicine and therapies · 2025Trial
- Depression and Mood Changes in People with Parkinson's Disease over Time: A 5-Year Follow-Up Study.Journal of personalized medicine · 2026Article
- The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention.EBioMedicine · 2026Article
- Caregiver burden of parkinsonian patients with impulse control disorders, depression and apathy.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Movement Disorder Patients with Depression Have Altered Corticostriatal Alpha-Beta Power Response to Reward and Loss.eNeuro · 2026Article
- Sex-specific differences and diagnostic tool performance in the neuropsychiatric profile of Parkinson's disease.BMC neurology · 2026Article
- Narrative Review of Body-First Versus Brain-First Prodromal Neuropsychiatric Symptoms in Parkinson's Disease.Cureus · 2026Review
- Physical frailty, depressive symptoms, and cognitive decline before and after Parkinson's disease diagnosis: a population-based prospective study of the SHARE and ELSA cohorts.NPJ Parkinson's disease · 2026Article
- Misfolded Proteins and Cognitive Decline: Mechanistic Insights into Neurodegenerative Disorders.Neurology international · 2026Review
- Bridging the Rural Mental Health Gap: Telehealth Delivery of Specialized CBT and MBCT for Veterans With Parkinson's Disease.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2026Article
- Diagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders.International journal of environmental research and public health · 2026Review
- Simulated depression risk classification from Parkinson's voice features using a self-attention-enhanced MLP architecture.Scientific reports · 2026Article
- Combined Effects of Depression, Fatigue and Cardiovascular Dysfunction on Functional Dependence Over Seven Years in Early Parkinson's Disease.Movement disorders clinical practice · 2026Article
- An interactive cascaded deep learning framework with expert refinement for accurate striatal subregion segmentation.Scientific reports · 2026Article
- Association between anxiety, depression, and fatigue in elderly patients with Parkinson's disease.World journal of psychiatry · 2026Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is one of the most frequent and burdensome non-motor symptoms in Parkinson's disease (PD), across all stages. Even when its severity is mild, PD depression has a great impact on quality of life for these patients and their caregivers. Accordingly, accurate diagnosis, supported by validated scales, identification of risk factors, and recognition of motor and non-motor symptoms comorbid to depression are critical to understanding the neurobiology of depression, which in turn determines the effectiveness of dopaminergic drugs, antidepressants and non-pharmacological interventions. Recent advances using in vivo functional and structural imaging demonstrate that PD depression is underpinned by dysfunction of limbic networks and monoaminergic systems, depending on the stage of PD and its associated symptoms, including apathy, anxiety, rapid eye movement sleep behavior disorder (RBD), cognitive impairment and dementia. In particular, the evolution of serotonergic, noradrenergic, and dopaminergic dysfunction and abnormalities of limbic circuits across time, involving the anterior cingulate and orbitofrontal cortices, amygdala, thalamus and ventral striatum, help to delineate the variable expression of depression in patients with prodromal, early and advanced PD. Evidence is accumulating to support the use of dual serotonin and noradrenaline reuptake inhibitors (desipramine, nortriptyline, venlafaxine) in patients with PD and moderate to severe depression, while selective serotonin reuptake inhibitors, repetitive transcranial magnetic stimulation and cognitive behavioral therapy may also be considered. In all patients, recent findings advocate that optimization of dopamine replacement therapy and evaluation of deep brain stimulation of the subthalamic nucleus to improve motor symptoms represents an important first step, in addition to physical activity. Overall, this review indicates that increasing understanding of neurobiological changes help to implement a roadmap of tailored interventions for patients with PD and depression, depending on the stage and comorbid symptoms underlying PD subtypes and their prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.